Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International

Wikipedia Affiliate Button

Home > Press > Arrowhead Pharmaceuticals to Present at Upcoming September 2018 Conferences

Abstract:
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to present at the following upcoming events:

Arrowhead Pharmaceuticals to Present at Upcoming September 2018 Conferences

Pasadena. CA | Posted on August 31st, 2018

Annual B. Riley FBR Healthcare Conference– New York, September 4, 2018

Bruce Given, M.D., Arrowhead’s chief operating officer, and Vincent Anzalone, CFA, vice president of investor relations, will participate in three panel discussions

18th World Gastroenterologists Summit – Auckland, New Zealand, September 7-8, 2018

September 7, 09:45 a.m. NZST – Dr. Given will deliver a keynote presentation titled, “Hepatitis B in focus: New biology, new targets and real hope for finite therapy”

European Respiratory Society International Congress 2018 – Paris, September 15-19, 2018

September 16, 12:15 p.m. CEST –Erik Bush, Ph.D., Arrowhead’s director of extra-hepatic targeting, will deliver an oral presentation titled, “Targeting ENaC with an epithelial RNAi trigger delivery platform for the treatment of cystic fibrosis”

Antivirals: Targeting HBV and Beyond – Boston, September 25, 2018

September 25, 12:00 p.m. EDT –James Hamilton, M.D., Arrowhead’s vice president of clinical development, will deliver an oral presentation titled, “Using siRNA to target the HBV transcriptome”

A copy of presentation materials may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website after the presentations conclude.

####

About Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.

For more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts .

Safe Harbor Statement under the Private Securities Litigation Reform Act:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the safety and efficacy of our product candidates, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the future success of our scientific studies, our ability to successfully develop drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

For more information, please click here

Contacts:
Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
626-304-3400

or
Investors and Media:
LifeSci Advisors, LLC
Brian Ritchie
212-915-2578

www.lifesciadvisors.com

Copyright © Arrowhead Pharmaceuticals, Inc.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Bosch Sensortec launches ideation community to foster and accelerate innovative IoT applications : Creativity hub for customers, partners, developers and makers February 18th, 2019

Exotic spiraling electrons discovered by physicists: Rutgers-led research could lead to advances in lighting and solar cells February 18th, 2019

Tracking pollen with quantum dots: A pollination biologist from Stellenbosch University in South Africa is using quantum dots to track the fate of individual pollen grains. This is breaking new ground in a field of research that has been hampered by the lack of a universal method February 17th, 2019

Super-light, super-insulating ceramic aerogel keeps the hottest temperatures at bay February 17th, 2019

Nanomedicine

Sensitive sensor detects Down syndrome DNA February 14th, 2019

Laser-induced graphene gets tough, with help: Rice University lab combines conductive foam with other materials for capable new composites February 12th, 2019

Nominations invited for $250,000 Kabiller Prize — the world’s largest monetary award for achievement in nanomedicine: An additional $10,000 award will honor a young investigator in nanoscience, nanomedicine February 7th, 2019

Kanazawa University research: Chirality inversion in a helical molecule at controlled speeds February 6th, 2019

Announcements

Bosch Sensortec launches ideation community to foster and accelerate innovative IoT applications : Creativity hub for customers, partners, developers and makers February 18th, 2019

Exotic spiraling electrons discovered by physicists: Rutgers-led research could lead to advances in lighting and solar cells February 18th, 2019

Tracking pollen with quantum dots: A pollination biologist from Stellenbosch University in South Africa is using quantum dots to track the fate of individual pollen grains. This is breaking new ground in a field of research that has been hampered by the lack of a universal method February 17th, 2019

Super-light, super-insulating ceramic aerogel keeps the hottest temperatures at bay February 17th, 2019

Events/Classes

Bosch Sensortec launches ideation community to foster and accelerate innovative IoT applications : Creativity hub for customers, partners, developers and makers February 18th, 2019

CEA-Leti Combines Integrated Optics and Holography In Novel Lens-Free, Augmented Reality Technology: Approach Eliminates the Need for Optical Systems and Combiners in AR; Will Be Presented at SPIE Photonics West 2019 February 6th, 2019

CEA-Leti Builds Prototype of Next-Generation Mid-Infrared Optical Sensors for Portable Devices: Coin-size, On-chip Sensors that Combine High Performance and Low Power Consumption Presented in Paper at SPIE Photonics West 2019 February 5th, 2019

CEA-Leti to Present 21 Papers at Photonics West & Unveil its Latest Research on Greater Photonics-Electronics and Software Convergence: Optics and Si-Photonics Teams Will Explain Transfer-Ready Solutions For Wavelength Imaging and Other Applications at Leti Booth, Feb. 5-7 February 1st, 2019

Nanobiotechnology

Sensitive sensor detects Down syndrome DNA February 14th, 2019

Nominations invited for $250,000 Kabiller Prize — the world’s largest monetary award for achievement in nanomedicine: An additional $10,000 award will honor a young investigator in nanoscience, nanomedicine February 7th, 2019

Kanazawa University research: Chirality inversion in a helical molecule at controlled speeds February 6th, 2019

Disruptive by Design: Nano Now February 1st, 2019

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project